辛伐他汀对老年急性冠状动脉综合征患者hsC和sICAM-1及预后的影响

Influence of simvastatin on the level of hsC,sICAM-1 and prognosis in aged acute coronary syndrome patients

目的:研究辛伐他汀对急性冠状动脉综合征(ACS)患者外周血清可溶性细胞间黏附分子-1(sICAM-1)、超敏C反应蛋白(hsC)和心血管事件预后的影响。方法:将73例经冠状动脉造影证实的ACS患者随机分为对照组35例和治疗组38例。对照组给予控制血压、降糖、抗凝、抗血小板及改善心肌供血等治疗,调脂药物采用血脂康治疗,治疗组在此基础上加用辛伐他汀20 mg。治疗前及治疗3周后,分别测定血总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、sICAM-1及hsC,观察2组患者出院后6个月内因不稳定型心绞痛再住院、急性心肌梗死、血运重建及死亡等MACE事件发生情况。结果:辛伐他汀治疗组TC、LDL-C、hsC、sICAM-1水平降低(P<0.05);6个月内的不良心脏事件(MACE)显著减少。结论:辛伐他汀可显著减少老年ACS患者MACE的发生率,降低血hsC、sICAM-1水平,改善预后。

Objective： To investigate the influence of simvastatin on the Level of hsC, sICAM-1 and prognosis in Acute Coronary Syndrome Patients. Method ：73 ACS patients confirmed with CAG were randomly divided into two groups, the control group and the experiment group. The control group the patients were given hypotensor, hypoglycemic, anti-platelet anti-coagulant, XUEZHIKANG , and myocardial blood supply improving remedies. The experiment group the patients were given simvastatin, based on the drugs in the control group. Before treatment, and 3 weeks after treatment, the levels of serum hsC, sICAM-1 and blood lipid were investigated;and at the same time, the incidences of unstable angina pectoris and acute myocardial infarction, and the events of vascular rebuilding and death were compared within 6 months between the two groups. Result： Within 6 months the hospitalization rate because of MACE was lower in the experimental group than that in the control group （P 〈 0.05）. Compared with the control group,the significant difference was found in the level of hsC,sICAM-1 and blood lipid （P 〈 0.05）. Conclusion： Simvastatin can significantly reduce the incidences of MACE and improve prognosis in ACS patients. It can lower the levels serum hsC and sICAM-1 in these patients.